IRON
HealthcareDisc Medicine, Inc. · Biotechnology · $3B
What is Disc Medicine, Inc.?
Disc Medicine, Inc. is a clinical-stage biotechnology company developing treatments for serious hematologic diseases. Headquartered in Watertown, Massachusetts, it was founded in 2020.
Disc Medicine builds a pipeline of therapeutic candidates targeting fundamental biological pathways in red blood cell biology — specifically heme biosynthesis and iron homeostasis. The company does not yet generate product revenue; it advances candidates through clinical development with the goal of commercializing treatments for patients with serious blood disorders.
Disc Medicine was founded in 2020 and is based in Watertown, Massachusetts.
- Heme biosynthesis pathway therapies
- Iron homeostasis-targeting candidates
- Clinical-stage hematologic disease pipeline
Is IRON a Good Stock to Buy?
UQS Score rates IRON as Poor overall, reflecting the early-stage nature of the business.
The Risk pillar stands out as the relative bright spot, suggesting the company's financial structure carries a degree of stability uncommon for its development stage.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue biotech that has yet to establish a commercial footprint. Valuation is rated Elevated.
See the full pillar breakdown and financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does IRON pay dividends?
No — Disc Medicine, Inc. does not currently pay a dividend.
Disc Medicine does not pay a dividend. As a clinical-stage company, available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions.
When does IRON report earnings?
Disc Medicine reports financial results on a quarterly cadence, typical for US-listed companies.
As a pre-revenue biotech, quarterly reports focus on pipeline progress, cash runway, and operating expenses rather than sales or earnings growth. Developments in clinical trial milestones tend to drive investor attention.
For the most recent quarter's results, visit Disc Medicine's investor relations page directly.
IRON Price History
-43.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Disc Medicine, Inc.?
Based on Disc Medicine, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Disc Medicine do?
Disc Medicine is a clinical-stage biotechnology company focused on discovering and developing treatments for serious hematologic diseases. Its pipeline targets core biological pathways in red blood cell biology, including heme biosynthesis and iron homeostasis.
Does IRON pay dividends?
No. Disc Medicine does not currently pay a dividend. Capital is reinvested into clinical development and pipeline programs, which is typical for early-stage biotech companies.
When does IRON report earnings?
Disc Medicine follows a standard quarterly reporting schedule. For exact dates, check the company's investor relations page, as our data source does not provide confirmed upcoming earnings dates.
Is IRON a good stock to buy?
UQS Score rates IRON as Poor overall. The Risk pillar is the relative strength, but Quality, Moat, and Growth are all Weak, and Valuation is Elevated. Investors should weigh these factors carefully against their own risk tolerance.
Is IRON overvalued?
The UQS Valuation pillar for IRON is rated Elevated, suggesting the current market price may not offer a margin of safety relative to the company's early-stage fundamentals.
What is IRON's market cap bracket?
Disc Medicine is classified as a mid-cap company based on current market capitalization.
Is IRON a long-term quality indicator?
Based on the UQS framework, IRON's long-term quality profile is currently rated Poor. Clinical-stage biotechs can improve materially if pipeline candidates succeed, but the present pillar scores reflect significant uncertainty.
What sector does IRON belong to?
Disc Medicine operates in the Healthcare sector, specifically within clinical-stage biotechnology, focusing on hematologic disease treatments.
Unlock Full IRON Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for IRON
- ✓Access detailed financial metrics and trend data
- ✓Compare IRON against hematology and biotech peers
- ✓Get the full analyst-style quality and risk assessment
Pro Analysis
IRON — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 73.0 | 0.0 | +4.0 |
| May 9, 2026 | 9.7 | 0.0 | 11.0 | 0.0 | 46.2 | 0.0 | -3.7 |
| Apr 2, 2026 | 13.4 | 0.0 | 11.0 | 0.0 | 71.2 | 0.0 | — |
IRON — Pillar Breakdown
Quality
— 0.0/100 (25%)Disc Medicine, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Disc Medicine, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.0/100 (15%)Disc Medicine, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Disc Medicine, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Disc Medicine, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IRON.
Score Composition
Financial Data
More Stock Analysis
How is the IRON UQS Score Calculated?
The UQS (Unified Quality Score) for Disc Medicine, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Disc Medicine, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Disc Medicine, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.